BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BTX-9341 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BTX-9341\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06515470-9058@assetmemo.bio
DTSTAMP:20261121T005341Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:BTX-9341: Phase 1 readout est. (NCT06515470)
DESCRIPTION:BTX-9341\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : Safety\, Tolerability\, Pharmacokinetics\, and Preliminary Efficacy of B
 TX-9341 in Advanced and/or Metastatic Breast Cancer\nEstimated primary com
 pletion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/btx-9341#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06515470
URL:https://assetmemo.bio/drug/btx-9341#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
